DSIJ Mindshare

Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

The inspection, conducted between December 9 and December 17, 2024, resulted in two procedural observations from the US FDA.

Manoj Reddy Sama 0 105 Article rating: 4.3

The facility in question, Unit-V, is an active pharmaceutical ingredient (API) manufacturing site operated by Apitoria Pharma Private Ltd, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram Village, Telangana.

 

Pharma penny stock under Rs 60 jumps after company received communication from EDQM on CEP filing of Propafenone HCl

From Rs 43.42 per share (52-week low) to Rs 54.90 per share, the stock is up by 26.40 per cent.

Kiran Shroff 0 757 Article rating: 4.0

From Rs 43.42 per share (52-week low) to Rs 54.90 per share, the stock is up by 26.40 per cent.

FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit

The company reported an impressive over 11 times growth in net profit for the second quarter of FY25, with Profit After Tax (PAT) reaching Rs 17.94 crore compared to Rs 1.61 crore in the same period last year.

Manoj Reddy Sama 2 902 Article rating: 4.0

Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) significantly increased their holdings in Shilpa Medicare during Q2 of FY25.

Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high

The shares of the company saw a spurt in volume by more than 2 times.

Kiran Shroff 0 357 Article rating: 5.0

The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years.

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

Pushkar Shinde 0 120 Article rating: 5.0

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

RSS
1234567
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR